{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Irinotecan+%28Camptosar%29&page=26", "query": { "intervention": "Irinotecan (Camptosar)", "page": 26 }, "page_size": 10 }, "pagination": { "page": 26, "page_size": 10, "total_count": 921, "total_pages": 93, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Irinotecan+%28Camptosar%29&page=27&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Irinotecan+%28Camptosar%29&page=25&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-16T05:01:32.067Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01479465", "title": "Efficacy and Safety of Simtuzumab (SIM) With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "Simtuzumab", "type": "BIOLOGICAL" }, { "name": "Placebo to match SIM", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 266, "start_date": "2011-12", "completion_date": "2015-02", "has_results": true, "last_update_posted_date": "2019-04-17", "last_synced_at": "2026-10-16T05:01:32.067Z", "location_count": 56, "location_summary": "Huntsville, Alabama • Gilbert, Arizona • Alhambra, California + 49 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Alhambra", "state": "California" }, { "city": "Bakersfield", "state": "California" }, { "city": "Burbank", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01479465" }, { "nct_id": "NCT01605318", "title": "Study of Labetuzumab Govitecan in Participants With Metastatic Colorectal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Colorectal Cancer", "Colon Cancer", "Rectal Cancer" ], "interventions": [ { "name": "Labetuzumab Govitecan (LG)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 92, "start_date": "2013-02-12", "completion_date": "2017-01-03", "has_results": false, "last_update_posted_date": "2024-01-24", "last_synced_at": "2026-10-16T05:01:32.067Z", "location_count": 7, "location_summary": "Santa Monica, California • Aurora, Colorado • Newark, Delaware + 4 more", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Newark", "state": "Delaware" }, { "city": "Goshen", "state": "Indiana" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01605318" }, { "nct_id": "NCT00021268", "title": "Tocladesine in Treating Patients With Recurrent or Progressive Metastatic Colorectal Cancer", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "tocladesine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": null, "start_date": "2001-04", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-08-02", "last_synced_at": "2026-10-16T05:01:32.067Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00021268" }, { "nct_id": "NCT00005818", "title": "SU5416 and Irinotecan in Treating Patients With Advanced Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Adenocarcinoma of the Colon", "Adenocarcinoma of the Rectum", "Recurrent Colon Cancer", "Recurrent Rectal Cancer", "Stage III Colon Cancer", "Stage III Rectal Cancer", "Stage IV Colon Cancer", "Stage IV Rectal Cancer" ], "interventions": [ { "name": "irinotecan hydrochloride", "type": "DRUG" }, { "name": "semaxanib", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 68, "start_date": "2000-03", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-01-23", "last_synced_at": "2026-10-16T05:01:32.067Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00005818" }, { "nct_id": "NCT00354744", "title": "High-Dose Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Metastatic Rhabdomyosarcoma or Ectomesenchymoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Sarcoma" ], "interventions": [ { "name": "dactinomycin", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "ifosfamide", "type": "DRUG" }, { "name": "irinotecan hydrochloride", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" }, { "name": "conventional surgery", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" }, { "name": "filgrastim", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "49 Years", "sex": "ALL", "summary": "Up to 49 Years" }, "enrollment_count": 109, "start_date": "2006-07", "completion_date": "2019-06-30", "has_results": true, "last_update_posted_date": "2020-01-29", "last_synced_at": "2026-10-16T05:01:32.067Z", "location_count": 143, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 118 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Downey", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00354744" }, { "nct_id": "NCT02049593", "title": "PARP Inhibitor BMN-673 and Temozolomide or Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Cancer", "Unspecified Adult Solid Tumor" ], "interventions": [ { "name": "PARP inhibitor BMN-673", "type": "DRUG" }, { "name": "temozolomide", "type": "DRUG" }, { "name": "irinotecan hydrochloride", "type": "DRUG" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 44, "start_date": "2014-06-12", "completion_date": "2019-10-07", "has_results": false, "last_update_posted_date": "2022-09-26", "last_synced_at": "2026-10-16T05:01:32.067Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02049593" }, { "nct_id": "NCT01004159", "title": "Cetuximab Plus Irinotecan in Colorectal Cancer Patients Who Progressed After Failure With Cetuximab Plus Irinotecan", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "cetuximab with irinotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 20, "start_date": "2009-09", "completion_date": "2012-05", "has_results": true, "last_update_posted_date": "2015-10-19", "last_synced_at": "2026-10-16T05:01:32.067Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01004159" }, { "nct_id": "NCT00394433", "title": "Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Esophageal Cancer", "Stomach Cancer" ], "interventions": [ { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 38, "start_date": "2006-09", "completion_date": "2016-10", "has_results": true, "last_update_posted_date": "2017-08-01", "last_synced_at": "2026-10-16T05:01:32.067Z", "location_count": 3, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00394433" }, { "nct_id": "NCT00042874", "title": "Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "alvocidib", "type": "DRUG" }, { "name": "irinotecan hydrochloride", "type": "DRUG" }, { "name": "fluorouracil", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 77, "start_date": "2002-05", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-06-04", "last_synced_at": "2026-10-16T05:01:32.067Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00042874" }, { "nct_id": "NCT01837862", "title": "A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Pilomyxoid Astrocytoma", "Pilocytic Astrocytoma", "Glioma, Astrocytic", "Optic Nerve Glioma", "Pleomorphic Xanthoastrocytoma", "Glioblastoma Multiforme", "Anaplastic Astrocytoma", "Gliosarcoma", "Diffuse Intrinsic Pontine Glioma", "DIPG", "Low-grade Glioma", "Brainstem Glioma" ], "interventions": [ { "name": "Mebendazole", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Julie Krystal", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 10, "start_date": "2013-10-22", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-08-06", "last_synced_at": "2026-10-16T05:01:32.067Z", "location_count": 1, "location_summary": "New Hyde Park, New York", "locations": [ { "city": "New Hyde Park", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01837862" } ] }